Peter J. Schmidt

Dr. Peter J. Schmidt


Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2015 in JAMA Psychiatry
Verified
Journal Article
Open access
PDF file
PSPeter J. Schmidt
Peter J. Schmidt
RDRivka Ben Dor
Rivka Ben Dor
PMPedro E. Martinez
Pedro E. Martinez
GGGioia M. Guerrieri
Gioia M. Guerrieri
VHVeronica L. Harsh
Veronica L. Harsh
DRDavid R. Rubinow
David R. Rubinow
Depression risk increases in perimenopause, and depression is cited1-3 as a primary reason for resuming menopausal hormone therapy (HT). Community-based epidemiologic studies4-8 have documented a 1.5- to 3-fold greater risk of first onset of depression and recurrent depression in women in perimenopause compared with those who are premenopausal or several years postmenopausal. Observational studies9-11 have reported the emergence of depressive symptoms after the discontinuation of HT in 5% to 10% of women.

1 February 2005 in Archives of General Psychiatry
Verified
Journal Article
Closed access
PDF file
PSPeter J. Schmidt
Peter J. Schmidt
RDRobert C. Daly
Robert C. Daly
MBMiki Bloch
Miki Bloch
MSMark J. Smith
Mark J. Smith
MDMerry A. Danaceau
Merry A. Danaceau
DRDavid R. Rubinow
David R. Rubinow
Research from JAMA Psychiatry — Dehydroepiandrosterone Monotherapy in Midlife-Onset Major and Minor Depression

1 October 2017 in American Journal of Psychiatry
Verified
Journal Article
Closed access
PSPeter J. Schmidt
Peter J. Schmidt
PMPedro E. Martinez
Pedro E. Martinez
LNLynnette K. Nieman
Lynnette K. Nieman
DKDeloris E. Koziol
Deloris E. Koziol
KTKarla D. Thompson
Karla D. Thompson
DRDavid R. Rubinow
David R. Rubinow

1 December 2004 in American Journal of Psychiatry
Verified
Journal Article
Closed access
PDF file
PSPeter J. Schmidt
Peter J. Schmidt
NHNazli Haq
Nazli Haq
DRDavid R. Rubinow
David R. Rubinow

1 October 2009 in Annals of the New York Academy of Sciences
Verified
Journal Article
Closed access
PDF file
PSPeter J. Schmidt
Peter J. Schmidt
DRDavid R. Rubinow
David R. Rubinow

14 August 2015 in Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
PMPedro E Martinez
Pedro E Martinez
DRDavid R Rubinow
David R Rubinow
LNLynnette K Nieman
Lynnette K Nieman
DKDeloris E Koziol
Deloris E Koziol
AMA Leslie Morrow
A Leslie Morrow
PSPeter J. Schmidt
Peter J. Schmidt
Changes in neurosteroid levels during the luteal phase of the menstrual cycle may precipitate affective symptoms. To test this hypothesis, we stabilized neurosteroid levels by administering the 5α-reductase inhibitor dutasteride to block conversion of progesterone to its neurosteroid metabolite allopregnanolone in women with premenstrual dysphoric disorder (PMDD) and in asymptomatic control women. Sixteen women with prospectively confirmed PMDD and 16 control women participated in one of two separate randomized, double-blind, placebo-controlled, cross-over trials, each lasting three menstrual cycles. After one menstrual cycle of single-blind placebo, participants were randomized to receive, for the next two menstrual cycles, either double-blind placebo or dutasteride (low-dose 0.5 mg/day in the first eight PMDD and eight control women or high-dose 2.5 mg/day in the second group of women). All women completed the daily rating form (DRF) and were evaluated in clinic during the follicular and luteal phases of each menstrual cycle. Main outcome measures were the DRF symptoms of irritability, sadness, and anxiety. Analyses were performed with SAS PROC MIXED. In the low-dose group, no significant effect of dutasteride on PMDD symptoms was observed compared with placebo (ie, symptom cyclicity maintained), and plasma allopregnanolone levels increased in women with PMDD from follicular to the luteal phases, suggesting the absence of effect of the low-dose dutasteride on 5α-reductase. In contrast, the high-dose group experienced a statistically significant reduction in several core PMDD symptoms (ie, irritability, sadness, anxiety, food cravings, and bloating) on dutasteride compared with placebo. Dutasteride had no effect on mood in controls. Stabilization of allopregnanolone levels from the follicular to the luteal phase of the menstrual cycle by blocking the conversion of progesterone to its 5α-reduced neurosteroid metabolite mitigates symptoms in PMDD. These data provide preliminary support for the pathophysiologic relevance of neurosteroids in this condition.